Efecto bimodal de la ciclofosfamida en la terapia antineoplásica
DOI:
https://doi.org/10.32635/2176-9745.RBC.1996v42n1.2880Palabras clave:
Ciclofosfamida, Metástases, Modificadores de la Respuesta Biológica, InmunomodulaciónResumen
La Ciclofosfamida (Cy) es el agente alquilante más utilizado en el tratamento quimioterápico de diversas neoplasias humanas; habitualmente se la administra em combinación con otros citostáticos para lograr una mayor eficacia terapêutica. La mayoría de los protoeolos clínicos la emplean en dosis altas y suministrada en repetidas ocaciones a lo largo del tratamento antineoplásico, con Ias ya conocidas acciones colaterales, entre ellas la inmunodepresión. Sin embargo, en diferentes modelos experimentales en animales portadores de un tumor, la administración de uma dosis única y relativamente baja en un determinado momento de la respuesta inmune antitumoral, produce inmunopotenciación, a través de una inhibieión selectiva sobre los linfocitos T supresores. Posteriormente se demostró un efecto interesante y novedoso de éstas dosis bajas de Cy: su acción preferencial sobre células tumorales com fenotipo metastásico (probablemente debido a una inmunomodulación selectiva sobre dichas subpoblaciones celulares), ya que se observo una inhibieión total en la formación de Ias metástasis sin afectar el desarrollo dei tumor primário. Estos resultados senalan el efecto bimodal de la Cy sobre el sistema inmune dei huésped cuando se la utiliza en el tratamiento antineoplásico em diferentes dosis y esquemas de administración. La utilización de sustancias naturales denominadas “modificadores de la respuesta biológica”, ha derivado en lo que se conoce como cuarta modalidad terapêutica contra el cáncer. Se propone que la Cy sea considerada también dentro de ese contexto.
Descargas
Citas
Gilman, A. - The initial clinical trial of nitrogen mustard. Am J Surg, 105: 574- 578, 1963. DOI: https://doi.org/10.1016/0002-9610(63)90232-0
Brock, N.; Wilmmans, H. - The action of a cyclic phosphamide ester of nitrogen mustard on experimental tumors in rats; therapeutic effects and pharmacological properties of B518 ASTA. Dtsch Med Wochenschr, 83: 453-458, 1958.
Goodman y Gilman - Las Bases Farmacológicas de la Terapêutica. T edición. Buenos Aires: Ed Médica Panamericana S.A., 1179, 1988.
Calabresi, P.; Welch, A.D. - Chemotherapy of neoplastic diseases. Annw Rev Med, 13: 147-202, 1962. DOI: https://doi.org/10.1146/annurev.me.13.020162.001051
De Vita, V.T.; Hellman, S.; Rosemberg, S.A. - Cancer: Principies and Practice of Oncology. Philadelphia: Lippincott Co, 1331, 1982.
Brock, N. Pharmacologic characterization of cyclophosphamide (NSC-26271) and cyclophosphamide metabolite. Cancer Chemother Rep, 51: 315-325, 1967.
Cooper, R.G.; Holland, J.F.; Glidewell, O. - Adjuvant chemotherapy of breast cancer. Cancer, 44: 793-798, 1979. DOI: https://doi.org/10.1002/1097-0142(197909)44:3<793::AID-CNCR2820440302>3.0.CO;2-Y
Buzdar, A.V.; Hortobagyi, G.N.; Smith, T.L. et al. - Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer, 62: 2098-2104, 1988. DOI: https://doi.org/10.1002/1097-0142(19881115)62:10<2098::AID-CNCR2820621005>3.0.CO;2-B
Buzdar, A.V.; Blumenschein, G.R.; Gutterman, J.U. et al. – Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide and BCG vaccine: A follow-up repoit JAMA, 242: 1609-1513, 1979. DOI: https://doi.org/10.1001/jama.242.14.1509
Kaplan, H.S. - Hodgkin’s disease: Unfolding concepts concerning its nature, management and prognosis. Cancer, 45: 2439-2474, 1980. DOI: https://doi.org/10.1002/1097-0142(19800515)45:10<2439::AID-CNCR2820451003>3.0.CO;2-1
Berard, C.W. - A multidisciplinar approach to non-Hodgkin’s lymphomas. Ann lnter Med, 94: 218-235, 1981. DOI: https://doi.org/10.7326/0003-4819-94-2-218
Petrini, B; Wasserman, J.; Blomgren, H.; Epsteom, S. - Changes of blood T cell subsets in patiens receiving postoperati ve adjuvant chemotherapy for breast cancer. EurJ Cancer Clin Oncol, 20.-1485-1487, 1984. DOI: https://doi.org/10.1016/0277-5379(84)90141-X
Ellis, G.K.; Green, S.; Schulman, S.; Tranum, B.; Goldberg, R.S.; Livingston, R.B. - Combination chemotherapy and high-dose cyclophosphamide for poor prognosis breast cancer. Cancer, 64: 2409-2415, 1989. DOI: https://doi.org/10.1002/1097-0142(19891215)64:12<2409::AID-CNCR2820641202>3.0.CO;2-T
Wooley, P.V.; Macdonald, J.S.; Schein, P.S. - Progress in Gastroenterology. New York: Grune & Stratton, 671, 1979.
Carbone, P.P. - Lung cancer, perspectives and prospects. Ann Inter Med, 73: 1003-1024, 1970. DOI: https://doi.org/10.7326/0003-4819-73-6-1003
Kyle, R.A.; Greipp, P.R. - Multiple myeloma and the monoclonal gammopathies. New York: Wiley, 261, 1981.
Kim, C.J.; Pak, K.; Hamaguchi, A.; Ishida, A.; Arai, Y; Konishi, T.; Okada, Y.; Tomotoshi, T. - Primary malignant melanoma of the urethra. Cancer, 71: 448-451, 1993. DOI: https://doi.org/10.1002/1097-0142(19930115)71:2<448::AID-CNCR2820710227>3.0.CO;2-Y
Bovbjerg, D.H.; Ader, R.; Cohen, N . - Fong-lasting enhancement of the delayed-type hypersensitivity response to heterologous erytrocytes in mice after a single injection of cyclophosphamide. Clin Exp Immunol, 66: 539-550, 1986.
Kaymakcalan, Z.; Spitalny, G.L.; Bursuker, I. - In vitro expression of secon-dary anti-tumor immunity by in vivo tumor-sensitized T cells: inhibition by tumor-induced suppressor T cells. Cancer Immunol Immunother, 25: 69-74, 1987. DOI: https://doi.org/10.1007/BF00199943
Kaplan, S.R.; Calabresi, P. - Drug therapy: immunosuppresive agents. N Engl J Med, 289: 952-954, 1973. DOI: https://doi.org/10.1056/NEJM197311012891806
Sardi, A.; Agnone, C.; Anderson, G.; Bolton, J.S.; Sundgaard-Riise, K.; Nieroda, C; Minton, J.P. - Fow-dose cyclo-phosphamide enhances helper-to-non helper ratios. Cancer Detec Prev, 15: 217-224, 1991.
Berd, D.; Maguire, H.C.; Mastrangelo, M.J. - Immune modulating agents. New York: Marcel Dekker, 39, 1985.
Berd, D.; Maguire, H.C.; Mastrangelo, M.J. - Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res, 44: 5439-5443, 1984.
Stevenson, H.C.; Fauci, A.S. – Activation of human B lymphocytes. Differencial effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immwnology, 39: 391-408, 1980.
Ozer, H .; Cowens, J.W.; Collins, M. et al. - In vitro effects of 4-hydroperoxy-cyclophosphamide on human immunore-gulatory T-subset function. J Exp Med, 155: 276-290, 1982. DOI: https://doi.org/10.1084/jem.155.1.276
Spreafico, F.: Vecchi, A.; Colotta, F.; Mantovani, A. - Cancer chemotherapeutics as immunomodulators. Springer Semin Immunophatol, S.-361-374, 1985. DOI: https://doi.org/10.1007/BF01857390
Spreafico, F.; Mantovani, A. - Immunomodulation by cancer chemotherapeutic agents and antineoplastic activity. Pathol Annual, 11: 177-205, 1981.
Berd, D.; Mastrangelo, M.J. - Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CDs+ subset. Cancer Res, 47: 3317-3321, 1987.
Turk, J.F.; Parker, D.; Cameron, A.E.P. - The effect of cyclophosphamide on immunological control mechanisms. Int J Tissue React, 6: 205-211, 1984.
Askenase, P.W.; Hayden, B.S.; Gershon, R.K. - Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 141: 697-702, 1975. DOI: https://doi.org/10.1084/jem.141.3.697
Ferguson, R.M.; Simmons, R.L. - Differential cyclophosphamide sensitivity of suppressor and cytotoxic cells precursors. Transplantation, 25: 36-41, 1978. DOI: https://doi.org/10.1097/00007890-197801000-00009
Mantovani, A. - The interaction of câncer chemotherapy agents with mononuclear phagocythes. Adv Pharmacol Chemother, 19: 35-47, 1983. DOI: https://doi.org/10.1016/S1054-3589(08)60020-4
Mastrangelo,M.J.; Berd, D.; Maguire, H. - The immunoaugmenting effects of câncer chemotherapeutics agents. Seminars in Oncology, 13: 186-194, 1986.
North, R.J. - Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med, 55: 1063-1074, 1982. DOI: https://doi.org/10.1084/jem.155.4.1063
Mokyr, M.B.; Colvin, M.; Dray, S. - Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Int J Immunopharmac, 7: 111-122,1985. DOI: https://doi.org/10.1016/0192-0561(85)90016-5
Maguire, H.C.; Ettore, V.L. - Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol, 48: 39-43, 1967. DOI: https://doi.org/10.1038/jid.1967.6
Lagrange, P.H.; Mackaness, G.B.; Miller, T.E. - Potentiation of T-cell mediated immunity by selective suppression of antibody formation with cyclophosphamide. J Exp Med, 139: 1529- 1545, 1974. DOI: https://doi.org/10.1084/jem.139.6.1529
Turk, J.L.; Parker, D.; Poulter, L.W. - Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide. Immunology, 23: 493-501, 1972.
Hengst, J.C.D.; Mokyr, M.B.; Dray, S. - Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOCP-315 tumors. Cancer Res, 41: 2163-2167, 1981.
Berendt, M.J.; North, R.J. - T-cell mediated suppression of anti-tumor immunity. Na explanation for progressive growth of an immunogenic tumor. J Exp Med, 151: 69-80, 1980. DOI: https://doi.org/10.1084/jem.151.1.69
Kaufmann, S.H.E.; Hah, H.; Diamantstein, T. - Relative susceptibilities of T- cell subsets involved in delayed-type hypersensitivity to sheep red blood cells to the in vitro action of 4-hydroperoxycyclophosphamide. J Immunol, 125: 1104-1108, 1980. DOI: https://doi.org/10.1007/978-94-010-9423-8_78
Hoover, S.K.; Barret, S.K.; Turk, M.T.; Lee, T.C.; Bear, H.D. - Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol Immunother, 31:121-127, 1990. DOI: https://doi.org/10.1007/BF01742376
Hengst, J.C.D.; Mokyr, M.B.; Dray, S. - Inportance of timming cyclophosphamide therapy for curing MOCP-315 tumor bearing mice. Cancer Res, 40: 2135-2143, 1980.
Sladek, N.E. - Therapeutic efficacy of cyclophosphamide as a function of its metabolism. Cancer Res, 32: 535-542, 1972.
Chassoux, D.M.; Gotoh, F.M.; Maclenan, I.C. - Analysis of synergy between cyclophosphamide therapy and immunity against mouse tumor. Br J Cancer, 38: 211-218, 1978. DOI: https://doi.org/10.1038/bjc.1978.190
Racca, A.L.; Celoria, G.C.; Hinrichsen, L.I.; Scharovsky, O.G.; Font, M.T. - Efecto de la ciclofosfamida sobre el crecimiento de un sarcoma transplantable de rata (S-EIOO). Medicina (Bs.As.), 48: 33-38, 1988.
Racca, A.L.; Scharovsky, O.G.; Celoria, G.C.; Font, M.T. – Inmunomodulación por ciclofosfamida de la respuesta anti-tumoral a un sarcoma de rata. Inmunología, 10: 91-96, 1991.
Racca, A.L. - Efecto de la ciclofosfamida sobre el crecimiento de un sarcoma transplantable (S-ElOO) en ratas endocriadas de la línea “m”. Tesis Doctoral, Fac. Cs. Bioq. y Farm. (UNR), 1988.
Rosemberg, S.A.; Packard, B.S.; Aebersold, P.M. et al. - Special report: Use of tumor-infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med, 319: 1676-1680, 1980. DOI: https://doi.org/10.1056/NEJM198812223192527
Mitchell, M.S.; Kemppf, R.A.; Harel, W. et al. - Effectiveness and tolerability of low dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol, 6: 409-411, 1988. DOI: https://doi.org/10.1200/JCO.1988.6.3.409
Berd, D.; Maguire, H.C.; Mastrangelo, M.J. - Induction of cell mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res, 46: 2572-2577, 1986.
Schirrmacher, V. - Cancer metastasis: Experimental approaches, theoretical concepts, and impacts for treatment strategies. Adv Cancer Res, 43: 1-73, 1985. DOI: https://doi.org/10.1016/S0065-230X(08)60942-2
Racca, A.L.; Scharovsky, O.G.; Celoria, G.C.; Pont, M.T. - Prevención de Ias metástasis de un linfoma de rata mediante el tratamiento con ciclofosfamida. Medicina (Bs.As.), 51: 395, 1991.
Celoria, G.C.; Pont, M.T.; Hinrichsen, L.I.; Scharovsky, O.G.; Racca, A.L. - Influencia del genotipo del huésped en la formación de Ias metástasis de un linfoma transplantabie de rata. Medicina (Bs.As.), 50: 230-234, 1990.
Isakov, N.; Peldman, M.; Segai, S. - Genetic regulation of metástasis progression the development of pulmonary of the 3LL lung carcinoma is controlled by both a non-H2 gene(s) and a gene(s) linked to the H2-D region of the mouse MHC. Transplanc Proc, 13: 778-782, 1981.
Collins, W.M.; Brown, D.W.; Ward, P.H.; Dunlop, W.R.; Elwood, B.W. - MHC and non-MHC genetic influences on Rous-Sarcoma naetastasis in chicken. Immunogenetics, 22: 315-321, 1985. DOI: https://doi.org/10.1007/BF00430915
Pont, M.T.; Celoria, G.C.; Scharovsky, O.G.; Racca, A.L. - Herencia de la susceptibilidad a los tumores y a Ias metástasis en roedores. Medicina (Bs.As.), 49: 258-264, 1989.
Scharovsky, O.G.; Matar, P.; Celoria, G.C., Pont, M.T. - Pfecto de la ciclofosfamida en en ensayo de metástasis experimental en rata..Medicina (Bs.As.), 52: 435, 1992.
Carmel, R.J., Brown, J.M. - The effect of cyclophosphamide and other drugs on the incidence of pulmonary metástases in mice. Cancer Res, 37: 145-151, 1977.
Van Putten, P.M.; Kram, L.K.J.; Van Dierendonck, H.H.C.; Smink, T.; Pusy, M. - Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection. Int J Câncer, 15: 588-595, 1975. DOI: https://doi.org/10.1002/ijc.2910150408
Liotta, L.A.; Stracke, M.L.; Wewer, U.M.; Schiffmann, E. - Pathobiology of Neoplasia, New York: Plenum Press, 533, 1989. DOI: https://doi.org/10.1007/978-1-4684-5523-6_28
Foon, K.A. - Biological response modifiers. The new immunotherapy. Cancer Res, 48: 1621-1639, 1989.
Matar, P.; Celoria, G.C.; Pont, M.T.; Scharovsky, O.G. - Antimetastatic effect of a single-low dose of cyclophosphamide on a rat lymphoma. J Exp Clin Cancer Res, (en prensa).
Mihich, E. - Future perspective for biological response modifiers: A view point. Semin Oncol, 13: 234-239, 1986.
